Process Development of the Synthetic Route to Sulamserod Hydrochloride
摘要:
Sulamserod hydrochloride is a potent 5-HT4 receptor antagonist and was a clinical candidate for the treatment of gastrointestinal disorders. Process development of the fairly long synthetic route (12 linear, 14 overall steps) was undertaken. Process improvements were highlighted by aromatic chlorination choices in making dichlorobenzodioxan 2 and acetylaminochloroketone 7, a transfer hydrogenation reducing a nitro group and simultaneous aromatic dechlorination without ketone reduction to give aminoketone 5, and use of the potential mutagenic iodosulfonamide 14 to make quaternary salt 11. The chemistry was scaled up into pilot plant reactor vessels to produce multikilogram amounts of Sulamserod hydrochloride suitable for drug development.
Compound of formula (I):
or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
化合物公式(I)或其药学上可接受的衍生物,并将其用作药物,特别是作为p38激酶抑制剂。
Process Development of the Synthetic Route to Sulamserod Hydrochloride
作者:Bruce A. Kowalczyk、Robinson、John O. Gardner
DOI:10.1021/op0002040
日期:2001.3.1
Sulamserod hydrochloride is a potent 5-HT4 receptor antagonist and was a clinical candidate for the treatment of gastrointestinal disorders. Process development of the fairly long synthetic route (12 linear, 14 overall steps) was undertaken. Process improvements were highlighted by aromatic chlorination choices in making dichlorobenzodioxan 2 and acetylaminochloroketone 7, a transfer hydrogenation reducing a nitro group and simultaneous aromatic dechlorination without ketone reduction to give aminoketone 5, and use of the potential mutagenic iodosulfonamide 14 to make quaternary salt 11. The chemistry was scaled up into pilot plant reactor vessels to produce multikilogram amounts of Sulamserod hydrochloride suitable for drug development.
[EN] BIPHENYL CARBOXYLIC AMIDE P38 KINASE INHIBITORS<br/>[FR] AMIDE BIPHENYLE CARBOXYLIQUE UTILISES EN TANT QU'INHIBITEURS DE LA KINASE P38
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004089874A1
公开(公告)日:2004-10-21
Compounds of formula (I) or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.